Shareholders of Zenas BioPharma, Inc. Urged to Participate in Class Action Lawsuit Following Losses

Overview of Allegations Against Zenas BioPharma, Inc.

Zenas BioPharma, Inc. (NASDAQ: ZBIO) has recently come under scrutiny as shareholders are encouraged to join a class action lawsuit initiated by The Gross Law Firm. This legal action stems from assertions that the company made materially false statements regarding its financial conditions around the time of its initial public offering (IPO) in September 2024. Investors who purchased shares during the specified timeframe are particularly urged to consider their involvement.

The Class Action Notice

The Gross Law Firm has published a notice targeting shareholders of ZBio following a significant decline in stock value after the IPO. In the statement released on June 5, 2025, the firm outlined the need for shareholders, especially those who incurred losses, to join the class action. This call to action is aimed at those who bought ZBIO securities based on the information presented in the registration statement and the subsequent prospectus associated with the IPO.

Key Allegations in the Case

According to the allegations included in the lawsuit, Zenas BioPharma's leadership is charged with having significantly overstated their capacity to sustain business operations by misrepresenting their existing cash flow and the expected funding from the IPO. The legal complaint highlights two main points:

1. Overstated Financial Projections: The defendants purportedly miscalculated the necessary support for ongoing operations, leading many investors to believe the company was on more stable financial ground than it truly was.
2. Misleading Public Statements: As a direct result of these misrepresentations, the public statements made by Zenas BioPharma were deemed to be significantly misleading both in terms of company prospects and overall stock performance.

Next Steps for Affected Shareholders

Shareholders who have suffered losses as a result of these alleged wrongful actions have until June 16, 2025 to register for the class action. The Gross Law Firm emphasizes that participation is free of charge, and being appointed as a lead plaintiff is not a requisite for recovery. Interested parties can easily register by filling out a submission form linked in the firm’s public notice. By enrolling, they will also gain access to portfolio monitoring software that will provide case updates.

Why Choose Gross Law Firm

The Gross Law Firm asserts its commitment to safeguarding the rights of investors who have faced adverse effects due to fraudulent practices. With a reputation for tackling deceptive corporate behavior, the firm has made it their mission to ensure companies adhere to ethical business practices. They aim to recover losses for investors who were misled, highlighting their proactive stance in addressing corporate misconduct.

Contact Information

For shareholders wishing to learn more or to register for the class action, they can contact The Gross Law Firm via the provided link or reach out directly through their official communication channels. The firm's address is:

15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

This situation underlines the importance of vigilance among investors, particularly during IPOs, and reinforces the need for transparent communication from corporations to their stakeholders. As the legal proceedings unfold, many await the developments of this case, hoping for a fair resolution to the grievances presented.